Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1984 Mar;49(3):307–313. doi: 10.1038/bjc.1984.48

Enhancement of nitrosourea cytotoxicity by misonidazole in vitro: correlation with carbamoylating potential.

R T Mulcahy, N L Dembs, G A Ublacker
PMCID: PMC1976738  PMID: 6704305

Abstract

We have investigated the relationships between nitrosourea structure and physicochemical properties and the ability of misonidazole (MISO) to potentiate nitrosourea cytotoxicity in an in vitro model system. EMT-6/Ro tumour cells were exposed in suspension to each of 9 different nitrosourea anti-tumour drugs under hypoxic and aerobic culture conditions. Additional cultures were similarly treated with nitrosoureas in the presence of 1.0 mM MISO. Seven of the 9 nitrosoureas did not demonstrate any selective toxicity toward aerobic or hypoxic cells. In contrast, chlorozotocin (CHLZ) was slightly more toxic toward hypoxic cells while Bis-OH CyNU more effectively killed aerobic cells. The addition of MISO to the drug treatment enhanced the effectiveness of all the nitrosoureas under hypoxic conditions, with the exception of CHLZ which was uninfluenced by MISO. The magnitude of the MISO dose enhancement factor (DEF, defined as the ratio of drug doses required to reduce cell survival to S = 10(-3) in 4 hours in the absence and presence of 1.0 mM MISO) for each combination was examined as a function of the relative carbamoylating or alkylating activity of the nitrosourea included in that combination. Such an analysis revealed a significant (P less than 0.05) positive correlation between relative carbamoylating potency and DEF. No significant (P greater than 0.20) relationship could be established for DEF and alkylating activity.

Full text

PDF
307

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Babson J. R., Reed D. J. Inactivation of glutathione reductase by 2-chloroethyl nitrosourea-derived isocyanates. Biochem Biophys Res Commun. 1978 Jul 28;83(2):754–762. doi: 10.1016/0006-291x(78)91053-7. [DOI] [PubMed] [Google Scholar]
  2. Bradley M. O., Sharkey N. A., Kohn K. W., Layard M. W. Mutagenicity and cytotoxicity of various nitrosoureas in V-79 Chinese hamster cells. Cancer Res. 1980 Aug;40(8 Pt 1):2719–2725. [PubMed] [Google Scholar]
  3. Brown J. M. The mechanisms of cytotoxicity and chemosensitization by misonidazole and other nitroimidazoles. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):675–682. doi: 10.1016/0360-3016(82)90711-8. [DOI] [PubMed] [Google Scholar]
  4. Kann H. E., Jr, Blumenstein B. A., Petkas A., Schott M. A. Radiation synergism by repair-inhibiting nitrosoureas in L1210 cells. Cancer Res. 1980 Mar;40(3):771–775. [PubMed] [Google Scholar]
  5. Lee F. Y., Workman P. Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice. Br J Cancer. 1983 May;47(5):659–669. doi: 10.1038/bjc.1983.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. McNally N. J. Enhancement of chemotherapy agents. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):593–598. doi: 10.1016/0360-3016(82)90691-5. [DOI] [PubMed] [Google Scholar]
  7. Montgomery J. A., James R., McCaleb G. S., Johnston T. P. The modes of decomposition of 1,3-bis(2-chloroethyl)-1-nitrosourea and related compounds. J Med Chem. 1967 Jul;10(4):668–674. doi: 10.1021/jm00316a033. [DOI] [PubMed] [Google Scholar]
  8. Mulcahy R. T. Chemical properties of nitrosoureas: implications for interaction with misonidazole. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):599–602. doi: 10.1016/0360-3016(82)90692-7. [DOI] [PubMed] [Google Scholar]
  9. Mulcahy R. T., Dembs N. Time-dose relationships for simultaneous misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea exposures in vitro. Cancer Res. 1983 Aug;43(8):3539–3543. [PubMed] [Google Scholar]
  10. Mulcahy R. T., Siemann D. W., Sutherland R. M. In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU. Br J Cancer. 1981 Jan;43(1):93–99. doi: 10.1038/bjc.1981.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mulcahy R. T., Siemann D. W., Sutherland R. M. Nitrosourea-misonidazole combination chemotherapy: effect on KHT sarcomas, marrow stem cells and gut. Br J Cancer. 1982 Jun;45(6):835–842. doi: 10.1038/bjc.1982.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Roizin-Towle L., Hall E. J., Flynn M., Biaglow J. E., Varnes M. E. Enhanced cytotoxicity of melphalan by prolonged exposure to nitroimidazoles: the role of endogenous thiols. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):757–760. doi: 10.1016/0360-3016(82)90729-5. [DOI] [PubMed] [Google Scholar]
  13. Schabel F. M., Jr Nitrosoureas: a review of experimental antitumor activity. Cancer Treat Rep. 1976 Jun;60(6):665–698. [PubMed] [Google Scholar]
  14. Siemann D. W. In vivo combination of misonidazole and the chemotherapeutic agent CCNU. Br J Cancer. 1981 Mar;43(3):367–377. doi: 10.1038/bjc.1981.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Siemann D. W., Mulcahy R. T. Cell survival recovery kinetics in the KHT sarcoma following treatment with five alkylating agents and misonidazole. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):619–622. doi: 10.1016/0360-3016(82)90697-6. [DOI] [PubMed] [Google Scholar]
  16. Siemann D. W. Potentiation of chemotherapy by hypoxic cell radiation sensitizers--a review. Int J Radiat Oncol Biol Phys. 1982 Jun;8(6):1029–1034. doi: 10.1016/0360-3016(82)90172-9. [DOI] [PubMed] [Google Scholar]
  17. Tannock I. F. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU. Br J Cancer. 1980 Dec;42(6):871–880. doi: 10.1038/bjc.1980.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Tannock I., Guttman P. Misonidazole increases the toxicity of BCNU for hypoxic cells. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):663–666. doi: 10.1016/0360-3016(82)90708-8. [DOI] [PubMed] [Google Scholar]
  19. Twentyman P. R. Sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea of the EMT6 tumor in vivo as determined by both tumor volume response and in vitro plating assay. Cancer Res. 1978 Aug;38(8):2395–2400. [PubMed] [Google Scholar]
  20. Weinkam R. J., Lin H. S. Chloroethylnitrosourea cancer chemotherapeutic agents. Adv Pharmacol Chemother. 1982;19:1–33. doi: 10.1016/s1054-3589(08)60019-8. [DOI] [PubMed] [Google Scholar]
  21. Wheeler G. P., Bowdon B. J., Grimsley J. A., Lloyd H. H. Interrelationships of some chemical, physicochemical, and biological activities of several 1-(2-haloethyl)-1-nitrosoureas. Cancer Res. 1974 Jan;34(1):194–200. [PubMed] [Google Scholar]
  22. Whillans D. W., Rauth A. M. An experimental and analytical study of oxygen depletion in stirred cell suspensions. Radiat Res. 1980 Oct;84(1):97–114. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES